197 related articles for article (PubMed ID: 31044748)
1. A randomized open label trial of tenofovir monotherapy versus tenofovir plus telbivudine in spontaneous reactivation of hepatitis B.
Jindal A; Vyas A; Sharma M; Kumar G; Sarin SK
Saudi J Gastroenterol; 2019; 25(5):319-326. PubMed ID: 31044748
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir Versus Entecavir for the Treatment of Acute-on-Chronic Liver Failure due to Reactivation of Chronic Hepatitis B With Genotypes B and C.
Wan YM; Li YH; Xu ZY; Wu HM; Xu Y; Wu XN; Yang JH
J Clin Gastroenterol; 2019 Apr; 53(4):e171-e177. PubMed ID: 29659382
[TBL] [Abstract][Full Text] [Related]
3. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Kim K; Kitrinos KM; Subramanian GM; McHutchison JG; Yee LJ; Elkhashab M; Berg T; Sporea I; Yurdaydin C; Husa P; Jablkowski MS; Gane E
J Hepatol; 2017 Jan; 66(1):11-18. PubMed ID: 27545497
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.
Suzuki F; Suzuki Y; Hosaka T; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
J Gastroenterol; 2017 May; 52(5):641-651. PubMed ID: 27699721
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of telbivudine and tenofovir disoproxil fumarate in preventing hepatitis B vertical transmission: A real-life practice.
Liu J; Wang J; Yan T; Du D; Qi C; Cao F; Yao N; Yang Y; He Y; Tian Z; Ren D; Zhu L; Chen T; Zhao Y
J Viral Hepat; 2019 Oct; 26(10):1170-1177. PubMed ID: 31177596
[TBL] [Abstract][Full Text] [Related]
7. Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.
Marcellin P; Ahn SH; Chuang WL; Hui AJ; Tabak F; Mehta R; Petersen J; Lee CM; Ma X; Caruntu FA; Tak WY; Elkhashab M; Lin L; Wu G; Martins EB; Charuworn P; Yee LJ; Lim SG; Foster GR; Fung S; Morano L; Samuel D; Agarwal K; Idilman R; Strasser SI; Buti M; Gaeta GB; Papatheodoridis G; Flisiak R; Chan HL
Aliment Pharmacol Ther; 2016 Nov; 44(9):957-966. PubMed ID: 27629859
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B.
Lee YB; Jung EU; Kim BH; Lee JH; Cho H; Ahn H; Choi WM; Cho YY; Lee M; Yoo JJ; Cho Y; Lee DH; Cho EJ; Yu SJ; Park SJ; Kim YJ; Park JW; Lee YJ; Kim CM; Yoon JH; Kim CY; Lee HS
Antimicrob Agents Chemother; 2015 Feb; 59(2):972-8. PubMed ID: 25421484
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.
Park H; Park JY; Kim SU; Kim DY; Han KH; Chon CY; Ahn SH
World J Gastroenterol; 2013; 19(43):7671-9. PubMed ID: 24431895
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure.
Garg H; Sarin SK; Kumar M; Garg V; Sharma BC; Kumar A
Hepatology; 2011 Mar; 53(3):774-80. PubMed ID: 21294143
[TBL] [Abstract][Full Text] [Related]
12. Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure.
Zoulim F; Białkowska-Warzecha J; Diculescu MM; Goldis AE; Heyne R; Mach T; Marcellin P; Petersen J; Simon K; Bendahmane S; Klauck I; Wasiak W; Janssen HL
Hepatol Int; 2016 Sep; 10(5):779-88. PubMed ID: 27206517
[TBL] [Abstract][Full Text] [Related]
13. Observational study on the response of tenofovir monotherapy versus tenofovir plus telbivudine dual therapy in patients with hepatitis B virus related acute on chronic liver failure.
Manik AH; Malakar D; Noor-E-Alam SM; Mahtab MA; Das DC; Mamun AA; Khan S; Akbar MF; Rahman Z; Rahman S
J Family Med Prim Care; 2021 Jun; 10(6):2376-2380. PubMed ID: 34322441
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections.
Gan W; Li J; Zhang C; Chen X; Lin C; Gao Z
BMC Infect Dis; 2020 Dec; 20(1):931. PubMed ID: 33287722
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
Lim YS; Byun KS; Yoo BC; Kwon SY; Kim YJ; An J; Lee HC; Lee YS
Gut; 2016 May; 65(5):852-60. PubMed ID: 25596179
[TBL] [Abstract][Full Text] [Related]
16. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
Berg T; Simon KG; Mauss S; Schott E; Heyne R; Klass DM; Eisenbach C; Welzel TM; Zachoval R; Felten G; Schulze-Zur-Wiesch J; Cornberg M; Op den Brouw ML; Jump B; Reiser H; Gallo L; Warger T; Petersen J;
J Hepatol; 2017 Nov; 67(5):918-924. PubMed ID: 28736139
[TBL] [Abstract][Full Text] [Related]
17. Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection.
Lee HW; Park JY; Lee JW; Yoon KT; Kim CW; Park H; Kim YS; Paik SK; Lee JI; Kim BK; Han KH; Ahn SH
Clin Gastroenterol Hepatol; 2019 Jun; 17(7):1348-1355.e2. PubMed ID: 30613003
[TBL] [Abstract][Full Text] [Related]
18. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
Piratvisuth T; Komolmit P; Tanwandee T; Sukeepaisarnjaroen W; Chan HL; Pessôa MG; Fassio E; Ono SK; Bessone F; Daruich J; Zeuzem S; Cheinquer H; Pathan R; Dong Y; Trylesinski A
PLoS One; 2013; 8(2):e54279. PubMed ID: 23390496
[TBL] [Abstract][Full Text] [Related]
19. Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance.
Kim DY; Lee HW; Song JE; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH; Park JY
J Med Virol; 2018 Mar; 90(3):497-502. PubMed ID: 29077211
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir
Rodríguez M; Pascasio JM; Fraga E; Fuentes J; Prieto M; Sánchez-Antolín G; Calleja JL; Molina E; García-Buey ML; Blanco MÁ; Salmerón J; Bonet ML; Pons JA; González JM; Casado MÁ; Jorquera F;
World J Gastroenterol; 2017 Nov; 23(41):7459-7469. PubMed ID: 29151700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]